SynAct Pharma to present at BioStock Investing in Life Science conference
Bitget2026/09/22 05:04- SynAct Pharma will present at BioStock Investing in Life Science 2026 on Sept. 22 in Stockholm.
- Management will attend LSX Congress USA 2026 in Boston on Sept. 22-24, including a panel session Sept. 22.
- Investor and partnering meetings planned at European MidCap Event 2026 on Sept. 30-Oct. 1 in Paris.
- Additional meetings set for Oct. 7-8 at Sachs Associates Biotech in Europe Forum in Basel.
- Bio Japan in Yokohama scheduled for Oct. 7-8, with management available for partner discussions.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
siRNA rising star ADARx (ADRX.US) launches $350 millions IPO, AbbVie subscribes to 4.9% of shares with a maximum investment of $100 millions
ADARx plans to raise $350 millions and list on Nasdaq. AbbVie will invest up to $100 millions to acquire a 4.9% stake, with a median valuation of $1.8 billions.
Roche (RHHBY.US) weight loss injection shows positive mid-term trial results: average weight loss of 15.5% over 48 weeks, blood sugar levels drop by 2.65%.
The experimental weight-loss injection enicepatide simultaneously lowered blood sugar and body weight in overweight or obese patients with type 2 diabetes during a mid-stage clinical trial.
SPAC company Silicon Valley Acquisition II (SVATU.US) applies for US stock IPO, aiming to raise up to 220 millions USD.
The blank-check company (SPAC) Silicon Valley Acquisition II submitted a filing to the U.S. Securities and Exchange Commission (SEC) on Monday, planning to raise up to 220 millions USD through an initial public offering (IPO).
China’s gold imports exceeded 1,000 tons by August, surpassing the total for all of 2025.
Crypto prices
More
